

Hemoglobinopathy Treatment Drug Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/H8065FDF3570EN.html>

Date: February 2022

Pages: 109

Price: US\$ 3,250.00 (Single User License)

ID: H8065FDF3570EN

Abstracts

This report contains market size and forecasts of Hemoglobinopathy Treatment Drug in Global, including the following market information:

Global Hemoglobinopathy Treatment Drug Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Hemoglobinopathy Treatment Drug market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Analgesics Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Hemoglobinopathy Treatment Drug include Bristol-Myers Squibb Company, GlycoMimetics, Pfizer, Anthera Pharmaceuticals, Eli Lilly and Company, Mast Therapeutics, Daiichi Sankyo Company, Novartis and Bluebird Bio, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hemoglobinopathy Treatment Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Hemoglobinopathy Treatment Drug Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Hemoglobinopathy Treatment Drug Market Segment Percentages, by Type, 2021 (%)

Analgesics

Antibiotics

ACE Inhibitors

Hydroxyurea

Others

Global Hemoglobinopathy Treatment Drug Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Hemoglobinopathy Treatment Drug Market Segment Percentages, by Application, 2021 (%)

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Global Hemoglobinopathy Treatment Drug Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Hemoglobinopathy Treatment Drug Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Hemoglobinopathy Treatment Drug revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Hemoglobinopathy Treatment Drug revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Bristol-Myers Squibb Company

GlycoMimetics

Pfizer

Anthera Pharmaceuticals

Eli Lilly and Company

Mast Therapeutics

Daiichi Sankyo Company

Novartis

Bluebird Bio

HemaQuest Pharmaceuticals

Emmaus Medical

Prolong Pharmaceuticals

Merck

Medunik USA

Sangamo Therapeutics

Global Blood Therapeutics

Alnylam Pharmaceuticals

Acceleron Pharma

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Hemoglobinopathy Treatment Drug Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Hemoglobinopathy Treatment Drug Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL HEMOGLOBINOPATHY TREATMENT DRUG OVERALL MARKET SIZE

- 2.1 Global Hemoglobinopathy Treatment Drug Market Size: 2021 VS 2028
- 2.2 Global Hemoglobinopathy Treatment Drug Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Hemoglobinopathy Treatment Drug Players in Global Market
- 3.2 Top Global Hemoglobinopathy Treatment Drug Companies Ranked by Revenue
- 3.3 Global Hemoglobinopathy Treatment Drug Revenue by Companies
- 3.4 Top 3 and Top 5 Hemoglobinopathy Treatment Drug Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Hemoglobinopathy Treatment Drug Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Hemoglobinopathy Treatment Drug Players in Global Market
 - 3.6.1 List of Global Tier 1 Hemoglobinopathy Treatment Drug Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Hemoglobinopathy Treatment Drug Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Hemoglobinopathy Treatment Drug Market Size Markets, 2021 & 2028

4.1.2 Analgesics

4.1.3 Antibiotics

4.1.4 ACE Inhibitors

4.1.5 Hydroxyurea

4.1.6 Others

4.2 By Type - Global Hemoglobinopathy Treatment Drug Revenue & Forecasts

4.2.1 By Type - Global Hemoglobinopathy Treatment Drug Revenue, 2017-2022

4.2.2 By Type - Global Hemoglobinopathy Treatment Drug Revenue, 2023-2028

4.2.3 By Type - Global Hemoglobinopathy Treatment Drug Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Hemoglobinopathy Treatment Drug Market Size, 2021 & 2028

5.1.2 Hospital Pharmacy

5.1.3 Retail Pharmacy

5.1.4 Online Pharmacy

5.2 By Application - Global Hemoglobinopathy Treatment Drug Revenue & Forecasts

5.2.1 By Application - Global Hemoglobinopathy Treatment Drug Revenue, 2017-2022

5.2.2 By Application - Global Hemoglobinopathy Treatment Drug Revenue, 2023-2028

5.2.3 By Application - Global Hemoglobinopathy Treatment Drug Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Hemoglobinopathy Treatment Drug Market Size, 2021 & 2028

6.2 By Region - Global Hemoglobinopathy Treatment Drug Revenue & Forecasts

6.2.1 By Region - Global Hemoglobinopathy Treatment Drug Revenue, 2017-2022

6.2.2 By Region - Global Hemoglobinopathy Treatment Drug Revenue, 2023-2028

6.2.3 By Region - Global Hemoglobinopathy Treatment Drug Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Hemoglobinopathy Treatment Drug Revenue, 2017-2028

6.3.2 US Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.3.3 Canada Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.3.4 Mexico Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Hemoglobinopathy Treatment Drug Revenue, 2017-2028

6.4.2 Germany Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.4.3 France Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.4.4 U.K. Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.4.5 Italy Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.4.6 Russia Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.4.7 Nordic Countries Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.4.8 Benelux Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Hemoglobinopathy Treatment Drug Revenue, 2017-2028

6.5.2 China Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.5.3 Japan Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.5.4 South Korea Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.5.5 Southeast Asia Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.5.6 India Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Hemoglobinopathy Treatment Drug Revenue, 2017-2028

6.6.2 Brazil Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.6.3 Argentina Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Hemoglobinopathy Treatment Drug Revenue, 2017-2028

6.7.2 Turkey Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.7.3 Israel Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.7.4 Saudi Arabia Hemoglobinopathy Treatment Drug Market Size, 2017-2028

6.7.5 UAE Hemoglobinopathy Treatment Drug Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Bristol-Myers Squibb Company

7.1.1 Bristol-Myers Squibb Company Corporate Summary

7.1.2 Bristol-Myers Squibb Company Business Overview

7.1.3 Bristol-Myers Squibb Company Hemoglobinopathy Treatment Drug Major Product Offerings

7.1.4 Bristol-Myers Squibb Company Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)

7.1.5 Bristol-Myers Squibb Company Key News

7.2 GlycoMimetics

7.2.1 GlycoMimetics Corporate Summary

7.2.2 GlycoMimetics Business Overview

7.2.3 GlycoMimetics Hemoglobinopathy Treatment Drug Major Product Offerings

7.2.4 GlycoMimetics Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)

7.2.5 GlycoMimetics Key News

7.3 Pfizer

7.3.1 Pfizer Corporate Summary

7.3.2 Pfizer Business Overview

7.3.3 Pfizer Hemoglobinopathy Treatment Drug Major Product Offerings

7.3.4 Pfizer Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)

7.3.5 Pfizer Key News

7.4 Anthera Pharmaceuticals

7.4.1 Anthera Pharmaceuticals Corporate Summary

7.4.2 Anthera Pharmaceuticals Business Overview

7.4.3 Anthera Pharmaceuticals Hemoglobinopathy Treatment Drug Major Product Offerings

7.4.4 Anthera Pharmaceuticals Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)

7.4.5 Anthera Pharmaceuticals Key News

7.5 Eli Lilly and Company

7.5.1 Eli Lilly and Company Corporate Summary

7.5.2 Eli Lilly and Company Business Overview

7.5.3 Eli Lilly and Company Hemoglobinopathy Treatment Drug Major Product Offerings

7.5.4 Eli Lilly and Company Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)

7.5.5 Eli Lilly and Company Key News

7.6 Mast Therapeutics

7.6.1 Mast Therapeutics Corporate Summary

7.6.2 Mast Therapeutics Business Overview

7.6.3 Mast Therapeutics Hemoglobinopathy Treatment Drug Major Product Offerings

7.6.4 Mast Therapeutics Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)

7.6.5 Mast Therapeutics Key News

7.7 Daiichi Sankyo Company

7.7.1 Daiichi Sankyo Company Corporate Summary

7.7.2 Daiichi Sankyo Company Business Overview

7.7.3 Daiichi Sankyo Company Hemoglobinopathy Treatment Drug Major Product Offerings

7.7.4 Daiichi Sankyo Company Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)

7.7.5 Daiichi Sankyo Company Key News

7.8 Novartis

7.8.1 Novartis Corporate Summary

7.8.2 Novartis Business Overview

7.8.3 Novartis Hemoglobinopathy Treatment Drug Major Product Offerings

7.8.4 Novartis Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)

7.8.5 Novartis Key News

7.9 Bluebird Bio

7.9.1 Bluebird Bio Corporate Summary

7.9.2 Bluebird Bio Business Overview

7.9.3 Bluebird Bio Hemoglobinopathy Treatment Drug Major Product Offerings

7.9.4 Bluebird Bio Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)

7.9.5 Bluebird Bio Key News

7.10 HemaQuest Pharmaceuticals

7.10.1 HemaQuest Pharmaceuticals Corporate Summary

7.10.2 HemaQuest Pharmaceuticals Business Overview

7.10.3 HemaQuest Pharmaceuticals Hemoglobinopathy Treatment Drug Major Product Offerings

7.10.4 HemaQuest Pharmaceuticals Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)

7.10.5 HemaQuest Pharmaceuticals Key News

7.11 Emmaus Medical

7.11.1 Emmaus Medical Corporate Summary

7.11.2 Emmaus Medical Business Overview

7.11.3 Emmaus Medical Hemoglobinopathy Treatment Drug Major Product Offerings

7.11.4 Emmaus Medical Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)

- 7.11.5 Emmaus Medical Key News
- 7.12 Prolong Pharmaceuticals
 - 7.12.1 Prolong Pharmaceuticals Corporate Summary
 - 7.12.2 Prolong Pharmaceuticals Business Overview
 - 7.12.3 Prolong Pharmaceuticals Hemoglobinopathy Treatment Drug Major Product Offerings
 - 7.12.4 Prolong Pharmaceuticals Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)
 - 7.12.5 Prolong Pharmaceuticals Key News
- 7.13 Merck
 - 7.13.1 Merck Corporate Summary
 - 7.13.2 Merck Business Overview
 - 7.13.3 Merck Hemoglobinopathy Treatment Drug Major Product Offerings
 - 7.13.4 Merck Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)
 - 7.13.5 Merck Key News
- 7.14 Medunik USA
 - 7.14.1 Medunik USA Corporate Summary
 - 7.14.2 Medunik USA Business Overview
 - 7.14.3 Medunik USA Hemoglobinopathy Treatment Drug Major Product Offerings
 - 7.14.4 Medunik USA Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)
 - 7.14.5 Medunik USA Key News
- 7.15 Sangamo Therapeutics
 - 7.15.1 Sangamo Therapeutics Corporate Summary
 - 7.15.2 Sangamo Therapeutics Business Overview
 - 7.15.3 Sangamo Therapeutics Hemoglobinopathy Treatment Drug Major Product Offerings
 - 7.15.4 Sangamo Therapeutics Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)
 - 7.15.5 Sangamo Therapeutics Key News
- 7.16 Global Blood Therapeutics
 - 7.16.1 Global Blood Therapeutics Corporate Summary
 - 7.16.2 Global Blood Therapeutics Business Overview
 - 7.16.3 Global Blood Therapeutics Hemoglobinopathy Treatment Drug Major Product Offerings
 - 7.16.4 Global Blood Therapeutics Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)
 - 7.16.5 Global Blood Therapeutics Key News

7.17 Alnylam Pharmaceuticals

7.17.1 Alnylam Pharmaceuticals Corporate Summary

7.17.2 Alnylam Pharmaceuticals Business Overview

7.17.3 Alnylam Pharmaceuticals Hemoglobinopathy Treatment Drug Major Product Offerings

7.17.4 Alnylam Pharmaceuticals Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)

7.17.5 Alnylam Pharmaceuticals Key News

7.18 Acceleron Pharma

7.18.1 Acceleron Pharma Corporate Summary

7.18.2 Acceleron Pharma Business Overview

7.18.3 Acceleron Pharma Hemoglobinopathy Treatment Drug Major Product Offerings

7.18.4 Acceleron Pharma Hemoglobinopathy Treatment Drug Revenue in Global Market (2017-2022)

7.18.5 Acceleron Pharma Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Hemoglobinopathy Treatment Drug Market Opportunities & Trends in Global Market

Table 2. Hemoglobinopathy Treatment Drug Market Drivers in Global Market

Table 3. Hemoglobinopathy Treatment Drug Market Restraints in Global Market

Table 4. Key Players of Hemoglobinopathy Treatment Drug in Global Market

Table 5. Top Hemoglobinopathy Treatment Drug Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Hemoglobinopathy Treatment Drug Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Hemoglobinopathy Treatment Drug Revenue Share by Companies, 2017-2022

Table 8. Global Companies Hemoglobinopathy Treatment Drug Product Type

Table 9. List of Global Tier 1 Hemoglobinopathy Treatment Drug Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Hemoglobinopathy Treatment Drug Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Hemoglobinopathy Treatment Drug Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Hemoglobinopathy Treatment Drug Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Hemoglobinopathy Treatment Drug Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Hemoglobinopathy Treatment Drug Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Hemoglobinopathy Treatment Drug Revenue,

(US\$, Mn), 2017-2022

Table 21. By Country - North America Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2023-2028

Table 30. Bristol-Myers Squibb Company Corporate Summary

Table 31. Bristol-Myers Squibb Company Hemoglobinopathy Treatment Drug Product Offerings

Table 32. Bristol-Myers Squibb Company Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)

Table 33. GlycoMimetics Corporate Summary

Table 34. GlycoMimetics Hemoglobinopathy Treatment Drug Product Offerings

Table 35. GlycoMimetics Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)

Table 36. Pfizer Corporate Summary

Table 37. Pfizer Hemoglobinopathy Treatment Drug Product Offerings

Table 38. Pfizer Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)

Table 39. Anthera Pharmaceuticals Corporate Summary

Table 40. Anthera Pharmaceuticals Hemoglobinopathy Treatment Drug Product Offerings

Table 41. Anthera Pharmaceuticals Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)

Table 42. Eli Lilly and Company Corporate Summary

Table 43. Eli Lilly and Company Hemoglobinopathy Treatment Drug Product Offerings

Table 44. Eli Lilly and Company Hemoglobinopathy Treatment Drug Revenue (US\$,

Mn), (2017-2022)

Table 45. Mast Therapeutics Corporate Summary

Table 46. Mast Therapeutics Hemoglobinopathy Treatment Drug Product Offerings

Table 47. Mast Therapeutics Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)

Table 48. Daiichi Sankyo Company Corporate Summary

Table 49. Daiichi Sankyo Company Hemoglobinopathy Treatment Drug Product Offerings

Table 50. Daiichi Sankyo Company Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)

Table 51. Novartis Corporate Summary

Table 52. Novartis Hemoglobinopathy Treatment Drug Product Offerings

Table 53. Novartis Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)

Table 54. Bluebird Bio Corporate Summary

Table 55. Bluebird Bio Hemoglobinopathy Treatment Drug Product Offerings

Table 56. Bluebird Bio Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)

Table 57. HemaQuest Pharmaceuticals Corporate Summary

Table 58. HemaQuest Pharmaceuticals Hemoglobinopathy Treatment Drug Product Offerings

Table 59. HemaQuest Pharmaceuticals Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)

Table 60. Emmaus Medical Corporate Summary

Table 61. Emmaus Medical Hemoglobinopathy Treatment Drug Product Offerings

Table 62. Emmaus Medical Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)

Table 63. Prolong Pharmaceuticals Corporate Summary

Table 64. Prolong Pharmaceuticals Hemoglobinopathy Treatment Drug Product Offerings

Table 65. Prolong Pharmaceuticals Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)

Table 66. Merck Corporate Summary

Table 67. Merck Hemoglobinopathy Treatment Drug Product Offerings

Table 68. Merck Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)

Table 69. Medunik USA Corporate Summary

Table 70. Medunik USA Hemoglobinopathy Treatment Drug Product Offerings

Table 71. Medunik USA Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)

Table 72. Sangamo Therapeutics Corporate Summary
Table 73. Sangamo Therapeutics Hemoglobinopathy Treatment Drug Product Offerings
Table 74. Sangamo Therapeutics Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)
Table 75. Global Blood Therapeutics Corporate Summary
Table 76. Global Blood Therapeutics Hemoglobinopathy Treatment Drug Product Offerings
Table 77. Global Blood Therapeutics Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)
Table 78. Alnylam Pharmaceuticals Corporate Summary
Table 79. Alnylam Pharmaceuticals Hemoglobinopathy Treatment Drug Product Offerings
Table 80. Alnylam Pharmaceuticals Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)
Table 81. Acceleron Pharma Corporate Summary
Table 82. Acceleron Pharma Hemoglobinopathy Treatment Drug Product Offerings
Table 83. Acceleron Pharma Hemoglobinopathy Treatment Drug Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Hemoglobinopathy Treatment Drug Segment by Type in 2021
- Figure 2. Hemoglobinopathy Treatment Drug Segment by Application in 2021
- Figure 3. Global Hemoglobinopathy Treatment Drug Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Hemoglobinopathy Treatment Drug Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Hemoglobinopathy Treatment Drug Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Hemoglobinopathy Treatment Drug Revenue in 2021
- Figure 8. By Type - Global Hemoglobinopathy Treatment Drug Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Hemoglobinopathy Treatment Drug Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Hemoglobinopathy Treatment Drug Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Hemoglobinopathy Treatment Drug Revenue Market Share, 2017-2028
- Figure 12. US Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Hemoglobinopathy Treatment Drug Revenue Market Share, 2017-2028
- Figure 16. Germany Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia Hemoglobinopathy Treatment Drug Revenue Market Share, 2017-2028
- Figure 24. China Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028

Figure 28. India Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Hemoglobinopathy Treatment Drug Revenue Market Share, 2017-2028

Figure 30. Brazil Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Hemoglobinopathy Treatment Drug Revenue Market Share, 2017-2028

Figure 33. Turkey Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Hemoglobinopathy Treatment Drug Revenue, (US\$, Mn), 2017-2028

Figure 37. Bristol-Myers Squibb Company Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. GlycoMimetics Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Pfizer Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Anthera Pharmaceuticals Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Eli Lilly and Company Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Mast Therapeutics Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Daiichi Sankyo Company Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Novartis Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Bluebird Bio Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. HemaQuest Pharmaceuticals Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Emmaus Medical Hemoglobinopathy Treatment Drug Revenue Year Over

Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Prolong Pharmaceuticals Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Merck Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. Medunik USA Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 51. Sangamo Therapeutics Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 52. Global Blood Therapeutics Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 53. Alnylam Pharmaceuticals Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 54. Acceleron Pharma Hemoglobinopathy Treatment Drug Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Hemoglobinopathy Treatment Drug Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/H8065FDF3570EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H8065FDF3570EN.html>